{
  "retracted": false,
  "timestamp": 1476403200000,
  "updates": [
    {
      "timestamp": 1557412889940,
      "identifier": {
        "doi": "10.1038/srep35509"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1038/srep33825"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Erratum: Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment"
}
